Blueprint Medicines ' Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019

CAMBRIDGE, Mass., June 3, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced updated data from the ongoing...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials